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Summary.-In tumour regrowth-delay experiments, the analysis of results in the higher dose ranges may be complicated by a dose-dependent proportion of nonrecurrent (cured) tumours, whose inclusion in the analysis is not straightforward.
A study of the relation of growth delay to cure has been carried out using a model of tumour response which assumes Poisson (single-cell) cure statistics and exponential regrowth kinetics of recurrent tumours, and which makes use of Monte Carlo simulation techniques to represent the effects of inter-tumour heterogeneity. This approach yields correction factors compensating for tumour cures in growth-delay experiments. For homogeneous tumour systems (all tumours and treatments identical) these corrections are small and not significantly different from corrections obtained using the "long delay" procedure suggested previously (Denekamp, 1980; Fowler et al., 1980) . For heterogeneous systems, however, correction factors increase with the heterogeneity of the system, and may become quite large.
It is concluded that the quantitative assessment of heterogeneity is required, and a possible approach to this is suggested. Should evaluation of heterogeneity prove feasible, it will allow more efficient use of tumour-response data, and may permit realistic estimates of clonogenic cell survival in situ.
ONE OF the most popular end-points of tumour response in situ to cytocidal treatment is the mean regrowth delay of recurrent tumours. Where, as in the lower dose-ranges of the treatment, all tumours are recurrent, calculation of mean or average delay for a treatment group presents no problem.
However, at least with the more effective treatment modalities, higher doses produce an increasing proportion of nonrecurrent (cured) tumours which yield no physically observable measure of growth delay at all. The calculation of an average growth delay for a treatment group which includes both recurrent and nonrecurrent tumours is less straightforward, and has led to some divergence of opinion as to how such an analysis should proceed (see Kallman & Begg, 1980 for a summary).
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One approach (Denekamp, 1980; Fowler et al., 1980) is to include nominal delays for non-recurrent tumours in the form of "long delays" (i.e. as the estimated time to tumour recurrence from a single surviving clonogen i.e. cell) and thus include cured tumours in the growthdelay data to be averaged. As shown by Fowler et al. (1980) this yields a pleasing consistency between enhancement-ratio estimates derived from growth delay and from curability (e.g. TCD50) endpoints in several experimental situations.
Despite the intuitive appeal of this approach, its formal mathematical status remains unexplored. Since the problem of making allowance for cured tumours in growth-delay experiments is a very common one, it may be worthwhile to attempt to develop a formal mathematical treatment.
The objectives of growth-delay experiments and the problem of non-recurrent tumours
In most experiments in which growth delay is measured, the object (not always explicit) is to use an end-point which reflects the degree of cellular de-population of the tumour by the treatment, in effect a measure of the level of clonogenic cell survival in treated tumours. The relation of clonogenic cell survival to observed growth delay is by no means straightforward, and is considerably complicated by factors such as the "tumour bed effect" and the possible existence of "second waves of delay" in some tumours (see McNally, 1974; Brown & Howes, 1974 , for a discussion) but it is unlikely that growth delay would be a popular end-point were it not considered to be (at least roughly) representative of the level of tumour-cell survival in situ. Indeed, if growth delay proves not to provide a valid index of the effectiveness of treatment in killing clonogenic cells (rather than, say, altering their growth characteristics) then its use in most situations (including the determination of "enhancement ratios") will have been misplaced. It is, therefore, advisable to check, where possible, the agreement (or otherwise) of growth delay and other assays, as carried out, for example, by McNally et al. (1978) for sensitizer enhancement ratios for misonidazole in vivo and in vitro.
Here we shall adopt the conventional view that the growth-delay end-point may indeed be used as a measure of the effectiveness of treatment in killing clonogenic tumour cells-of reducing the tumour-cell population to a certain survival level. In such cases, it is required that the mean growth delay for a tumour group should adequately reflect the mean cell-survival level within the group as a whole, not some atypical survival level for some atypical sub-group of tumours. Unfortunately, for treatments within the range of curability, growth delay can be directly assigned only to tumours which are seen to recur; i.e. to the sub-group least affected by the treatment. The subgroup most affected by the treatment ("cured" tumours) do not recur and therefore provide no observed data for calculation of growth delay. Herein lies the potential for bias by neglecting "cured" tumours in growth-delay experiments, and thus the need for some statistically fair way of taking account of them.
The homogeneous Poi8son mnodel for tumour cure and recurrence Consider a population of identical tumours, each containing an identical number of clonogenic tumour cells, any one of which is capable of repopulating the tumour (note that this condition excludes immunogenic tumours). A true "cure" (no recurrence however long delayed) therefore requires elimination of all clonogenic cells, so that each cured tumour contains no surviving clonogenic cells after treatment.
However, for most cytocidal agents (radiation, most drugs) cell kill is a random process, whereby, at any given dose level, each clonogenic cell has a probability of being eliminated or of surviving. Hence, in a group of tumours given the same treatment, a proportion of tumours will be cured (no surviving clonogenic cells) and a proportion will recur (at least one surviving clonogenic cell).
Thus, in a group of K treated tumours, the first tumour may have N1 surviving cells, the second N2 and so on, the Kth tumour having NK cells, some of these N values (those for the cured tumours) being zero.
Let N denote the arithmetic average for the whole group. This is a situation to which Poisson statistics is readily applied, and it has been shown by several authors (e.g. Munro & Gilbert, 1961) in the Table, the last column of which gives the ratio of NR to N, which reflects the magnitude of the difference. As may be seen from the Table, and graphically, from Fig. 1 , the magnitude of the ratio NR/N increased rapidly beyond a Pc of about 0.5, becoming very large at high levels of tumour cure. Indeed, the factor has no finite limit and is theoretically infinite at total (100%) curability.
It is this factor which causes the bias when cured tumours are ignored in the results of growth-delay experiments.
Effect of inter-tumour heterogeneity on distributions of surviving clonogenic cells
In the preceding analysis, it was explicitly assumed that the tumour system was perfectly homogeneous (i.e. all tumours identical, all treatments identical). This is, of course, an unattainable ideal to which real systems approximate more or less well. More generally, inter-tumour heterogeneity will occur, and it is important to consider its effects. Inter-tumour heterogeneity, in the form of variable sensitivity to treatment, or, equivalently, of treatment dose received, is especially likely to occur in the case of treatment modalities for which uniformity of dose is difficult to achieve (e.g. hyperthermia, cytotoxic chemotherapy) resulting in the non-equivalence of individual tumours within the same treatment group.
In the present study, the effect of intertumour heterogeneity has been investigated using a Monte Carlo simulation model, described in the Appendix. Briefly, each individual tumour was assigned a sensitivity parameter (Do) randomly selected from a normal distribution of Do values with specified mean and standard deviation. The standard deviation of the sensitivity distribution then provides a measure of the level of heterogeneity. The theoretical fraction of surviving cells for each individual tumour subjected to a given treatment dose was calculated using a multi-target function for the randomly assigned Do; the theoretical surviving cell number (which could be an integer or fractional) was then taken as the mean of a Poisson distribution, and a random number selected from this distribution to represent the actual number of surviving cells (an integer or zero) for each tumour. Tumours assigned zero surviving cells were deemed cured and those assigned at least one surviving cell were deemed recurrent.
By carrying out a large number of such simulations for a range of treatment doses, and by varying the standard deviation of the sensitivity (Do) distribution, it was possible to study the effects of the sim- The results, depicted in Fig. 2 , show that inter-tumour heterogeneity may have a profound effect on the numbers of surviving cells, averaged over all tumours, or over recurrent tumours only. The discrepancy factor N/SR is strongly influenced by the heterogeneity and increases with the fractional standard deviation of the sensitivity distribution. It is not difficult to see how this comes about. In heterogeneous systems, the more sensitive tumours are cured at treatment dose levels which leave relatively large numbers of surviving cells in the more resistant tumours. Since the recurrent tumours are likely to be the more resistant ones, a large discrepancy may develop between the average number of surviving cells per tumour (N) and per recurrent tumour (NR). The practical effect of this is that 711-I.Q ;i. Steel, 1977 for discussion). The Gompertzian phase may, in itself, lead to some complications in the interpretation of growth delay experiments (Begg, 1980 Equation (5), used with the surviving cell numbers previously generated by the Monte Carlo procedure, allows calculation of the mean growth delay for the recurrent tumours at each dose. Since, in reality, only tumours which are recurrent yield measurable growth delay, this growth delay (fR) is the growth delay which would be observed experimentally.
Suppose, however, that a tumour was capable of regrowing from less than 1 cell (e.g. 041 cell or 0 01 cell). Such a tumour would, of course, have a longer growth delay than the longest physically possible time (for growth from a single cell) and this could be calculated using a similar equation to equation (7). Fractional mean levels of cell survival do indeed result from calculation of the effects of large treatment doses, using any continuous survival model. (E.g., an initial population of 108 cells would be reduced to 0.1 cells by a treatment giving a 10-9 surviving fraction.) 
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Though physical regrowth from less than one cell is, of course, biologically impossible, the theoretical regrowth delay time is easily calculated, so that the "regrowth time" of cured tumours can be included in the analysis. When the regrowth delay of all tumours (including those deemed cured) are calculated in this way, the individual growth delay may then be averaged as before to yield ;, the mean growth delay for all tumours in the group. In this way it is possible to calculate a theoretical mean growth delay for all tumours and to compare it with the corresponding growth delay for the recurrent tumours only. To facilitate comparison, it is useful to define a "cure correction factor" (F) given by:
F= T/TR (6) or F =FInR (7) i.e. the correction factor F is the quantity by which the observed mean regrowth delay (fR) must be multiplied, in order to obtain the theoretical mean regrowth delay (z) which takes account of cured tumour.
Using the mathematical model and Monte Carlo simulation procedure described in the Appendix, the cure-correction F factor has been calculated as a function of the proportion of tumours cured (Pc*) in each dose group, and as a function of the heterogeneity of the system, i.e. as a function of the standard deviation of the sensitivity (Do) distribution.
The results are shown in Fig. 3 . As may be seen, the F factor rises as a function of the cured proportion, and is also greater for greater heterogeneity. For perfectly homogeneous systems (zero variation of Do), the factor rises slowly from 1-00 (at a zero proportion of tumour cures) to a value of 1 04 at a cured proportion of 0.50. This is a very modest correction, and implies that neglect of cured tumours produces no serious error in perfectly homogeneous tumour systems.
However, the magnitude of the correction factor increases with the heterogeneity. For a heterogeneity corresponding to 25% standard deviation of the sensitivity distribution, the F factor has risen to 1-17 for a cured proportion of 0 50 and to 1-32 by a cured proportion of 0-80. This is a rather more serious correction and indicates that neglect of cured tumours in such a tumour system could lead to significant under-estimation of the effect of treatment.
It is instructive to compare these numerical properties of the F factor with the "long delay" correction procedure suggested previously (Denekamp, 1980; Fowler et al., 1980) to allow for cured tumours in growth-delay experiments. In this case, an "F factor" for the "long delay" procedure (FLD) may be calculated by taking the ratio of the mean growth delay obtained by assigning a "long delay" (here taken to be the time to regrow from a single cell) to cured tumours, to the mean delay for recurrent tumours only.
For the heterogeneity levels previously considered, the "long delay" correction factor was compared with the factor derived here. For homogeneous systems, and for only slightly heterogeneous systems, these factors were both small in magnitude and did not differ significantly. As the heterogeneity increased however, the F factor derived here increased rapidly 1501- and more consistently than the "long delay" factor. This effect is illustrated in Fig. 4 , which compares the two correction factors for heterogeneity corresponding to 25% standard deviation in the sensitivity (Do) distribution. Evidently, the "long delay" procedure could seriously underestimate the importance of cured tumours in growth-delay experiments involving the more heterogeneous tumour systems.
A possible approach to the quantitative assessment of heterogeneity There seems little prospect of precisely correcting for cured tumours in growthdelay experiments unless the heterogeneity present can be quantified. This seems a daunting prospect, but an approach to the problem may be possible.
In a perfectly homogeneous system, no cures should be observed until the mean number of surviving cells per tumour becomes very low. Thereafter, a small increase in treatment dose should lead to a rapid rise in the proportion of cures.
In heterogeneous systems, however, the more sensitive tumours will be cured whilst the more resistant tumours regrow from appreciable numbers of surviving cells. Considerable increase in treatment dose may be necessary before the more resistant tumours are cured. These considerations suggest that comparison of the observed regrowth delay (for recurrent tumours) to the proportion cured may indicate the heterogeneity present in the tumour system. This is illustrated in Fig. 5 , which shows the relation of observed growth delay to proportion cured for varying levels of heterogeneity. As expected, the observed growth delay rises steeply to its plateau value (the time to regrow from a single cell) for homogeneous systems, but the approach to the plateau level becomes progressively less steep as the heterogeneity increases. It is possible, therefore, that the shape of the curve relating observed growth delay to proportion cured could be used to indicate the level of heteterogeneity.
At the very least, a steep rise to the plateau level of growth delay provides confidence that the system under study is relatively homogeneous (and that neglect of cured tumours in growth-delay experiments is relatively unimportant) whilst a shallow rise provides a warning of possible heterogeneity (and a potentially serious effect of neglecting tumour cures). Since, in general, homogeneous experimental systems are preferable to heterogeneous ones, this may provide a further criterion for judging the suitability of the current experimental system. However, further work is necessary to determine the practical feasibility of this approach, and the extent to which complicating factors may intrude. Amongst the complicating factors which require to be considered are the growth-kinetic changes which may accompany treatment (McNally, 1974; Brown & Howes, 1974;  Stephens & Peacock, 1977) and which are already known to complicate the interpretation of growth-delay experiments. The effects of growth-rate variations amongst regrowing tumours, and the importance of sample size also require further consideration.
However, it seems possible that the relation of growth delay to cure could provide a rough estimate of heterogeneity, and such an approach may be worth further investigation.
CONCLUSIONS
(1) In homogeneous tumour systems, the observed regrowth delay rises steeply, with proportion cured, to a plateau level. In such systems, only a small correction need be applied to the observed growth delay to allow for cured tumours; this correction is equally well made using the "long delay" procedure or from information presented in this paper.
(2) In non-homogeneous systems, the relation of observed delay to proportion cured rises more slowly. In such systems, neglect of cured tumours in growth-delay experiments may lead to a serious underestimation of the effectiveness of treatment. The "long delay" procedure will, in general, provide correction factors which are too small, again leading to underestimation of the effectiveness of treatment. Accurate correction factors cannot be derived without knowledge of the heterogeneity of the system. (3) It is possible that the relationship of observed growth delay to proportion cured might provide estimates of the level of heterogeneity. Then, accurate correction factors could be derived. It is also possible that such information could be used to allow the reliable estimation of clonogenic cell survival in situ.
Monte Carlo methods comprise that branch of experimental mathematics which may be used to simulate random physical processes using sequences of suitably distributed random numbers, and takes place using a computer rather than a laboratory.
The present investigation uses random numbers, first to introduce known degrees of heterogeneity in radiosensitivity into otherwise identical populations of tumours, and then to simulate the response of the individual members of these "experimental" populations to the random physical process of radiation cell kill, modelled by Poisson statistics.
Random number generator
The random numbers used depend upon a common source of uniformly distributed. random numbers, generated using a multiplicative congruential generator (modulus 247 and generator 515), investigated by Coveyou & MacPherson (1967) ; and upon a number of machine-independent computer subroutines described and tested by McGrath & Irving (1975) , here implemented on a Data General Nova 1200 Computer in Fortran.
Tumour system
The tumour system studied in these simulations is characterized by the following Simulations From this set of parameters 9 distinct "experimental" populations were constructed, each comprising 50 tumours, whose individual radiosensitivities (Doi) are randomly selected from a normal distribution of Do values with a mean value of 3 0 Gy and, for each population, a certain heterogeneity, H, expressed as s.d. as a percentage of this mean. Computationally, the random selection of elements from a normal distribution with a known mean (Do) and standard deviation (HDO) was made with an efficient algorithm written by Marsaglia & Bray (1964) . The responses of each of these 9 populations to a range of single radiation doses was simulated in a process which, if carried out in the laboratory, would require at least 204 separate irradiations and the use of at least 10,200 tumour bearing animals.
For each individual tumour characterized by its randomly attributed radiosensitivity, Doi, the average number of cells, Ni, expected to survive a single radiation dose, D (were there many such identical tumours); may be calculated theoretically from the high-dose approximation to the multitarget equation: Computationally, the random selection of elements from a Poisson distribution was effected using a subroutine described by McGrath & Irving (1975) except in those cases where Ni > 10 cells, where an approximating normal distribution was used in the interests of efficiency. For each population and dose level, those tumours assigned zero cells by this process, were considered cured and the corresponding proportion termed "the observed cure probability", Pd*. The radiation dose range used for each population was adjusted so that this probability always encompassed the range 041-0 9. Dose increments of 1D0 Gy were adhered to throughout. For each population and dose level, those tumours assigned one or more surviving cells were assumed to recur, constituting a population subgroup from which "observations" of regrowth delay are made. The geometric average cell number NR, in this subgroup may be obtained from the relation: l M1 lnNR= lnNi;
Ni$0 (9) where M is the number of recurrent tumours in a given population. The dependence of the discrepancy factor (NRIN) upon the degree of population heterogeneity may now be investigated (see Fig. 2 ).
